AI-guided treatment for older adults with large B-cell lymphoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether an AI-based tool can help choose the best treatment for older adults with large B-cell lymphoma who are not fit for standard chemotherapy. It compares a personalized AI strategy with a standard two-drug regimen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years old or older and have been diagnosed with large B-cell lymphoma.
- You have not had chemotherapy or other anti-lymphoma drugs before (steroids are allowed).
- You have at least one measurable tumor site.
- Your doctor has assessed you as 'unfit' or 'frail' for standard treatment, or you have chosen not to have immunochemotherapy.
- You have had one cycle of a two-drug treatment (ZR2) and an AI test shows you are at intermediate or high risk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a computer-guided treatment plan can work as well as or better than the standard chemo-immunotherapy for large B-cell lymphoma. It uses a special test after the first cycle to decide who needs a more aggressive approach.
This study tests whether a new three-drug combination (Pola-ZR-Glo) works safely and effectively for older adults with a type of blood cancer called large B-cell lymphoma who cannot or prefer not to receive standard chemotherapy. The goal is to find a gentler treatment option for frail or elderly patients.
This trial tests a new combination of drugs (Pola-ZR2) against a standard combination (ZR2) for older adults with newly diagnosed diffuse large B-cell lymphoma. It aims to see if the new mix is more effective and safe.
This trial tests a new drug combo for people with an aggressive type of large b-cell lymphoma. It aims to see if adding the new drug to standard chemo plus an antibody therapy is safe and works better.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests a combination of two immunotherapy drugs (rimegepant and glofitamab) plus a special cell therapy called CD19 CAR-T for people with large B-cell lymphoma that has not responded to or has returned after previous treatment. The goal is to see if this combination can better control the lymphoma and improve outcomes.
Hear when a new Large B-Cell Lymphoma (LBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.